checkAd
    Regeneron Pharmaceuticals Aktie
    955,76
     
    USD
    -1,46 %
    -14,21 USD
    Letzter Kurs 08.05.24 Nasdaq
    955,25
     
    USD
    700 STK
    Geldkurs 08.05.24
    955,97
     
    USD
    100 STK
    Briefkurs 08.05.24
    ISIN: US75886F1075 · WKN: 881535 · SYM: RQP · USA

    Neueste Nachrichten

    Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
    08.05.24 · globenewswire · Regeneron Pharmaceuticals
    Regeneron Announces Investor Conference Presentations
    06.05.24 · globenewswire · Regeneron Pharmaceuticals
    Chartgalerie - Top / Flop Aktien Wochenrückblick Kalenderwoche 18/24
    04.05.24 · wO Chartvergleich · American Express
    Regeneron Reports First Quarter 2024 Financial and Operating Results
    02.05.24 · globenewswire · Regeneron Pharmaceuticals
    EYLEA HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
    29.04.24 · globenewswire · Regeneron Pharmaceuticals
    Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
    25.04.24 · globenewswire · Regeneron Pharmaceuticals
    Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
    24.04.24 · globenewswire · Regeneron Pharmaceuticals
    Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
    22.04.24 · globenewswire · Regeneron Pharmaceuticals
    The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
    17.04.24 · Business Wire (engl.) · Regeneron Pharmaceuticals
    Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
    07.04.24 · globenewswire · Regeneron Pharmaceuticals
    Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
    01.04.24 · globenewswire · Regeneron Pharmaceuticals
    Regeneron Provides Update on Biologics License Application for Odronextamab
    25.03.24 · globenewswire · Regeneron Pharmaceuticals